Publications:53
- Home
- Profiles
Megan L Shaw, PhD
- About Me
- Education & Certifications
- Research
- Locations
- Publications
- Industry Relationships
About Me
Language
Position
Research Topics
Antivirals, Biodefense, Immune Antagonism, Infectious Disease, Influenza Virus, Nipah Virus, Viruses and Virology
Multi-Disciplinary Training Areas
Microbiology [MIC]
About Me
Language
Position
Research Topics
Antivirals, Biodefense, Immune Antagonism, Infectious Disease, Influenza Virus, Nipah Virus, Viruses and Virology
Multi-Disciplinary Training Areas
Microbiology [MIC]
Education
BSc, University of Cape Town
BSc (Med)Honors, University of Cape Town
PhD, University of Glasgow
Research
The Shaw laboratory is interested in the interactions that occur between RNA viruses and their hosts at the molecular level and how this knowledge may be used for understanding viral pathogenesis and for developing new antiviral drugs. The research involves basic molecular biology and virology techniques combined with RNAi, proteomics and high-throughput screening of small molecular weight compounds.
Our major focus is on identifying new antivirals for influenza virus as well as host proteins that are required by the virus and therefore may serve as novel drug targets. Another interest of the Shaw lab is the host antiviral response and specifically the mechanisms that viruses use to block this response. One virus of particular interest to us is Nipah virus, with is a highly pathogenic, emerging paramyxovirus. Nipah virus encodes multiple proteins that inhibit the antiviral response and our goal is to determine their mechanisms of action and their individual contributions to virus pathogenesis.
Locations
Publications
Selected Publications
- Frequency, kinetics and determinants of viable SARS-CoV-2 in bioaerosols from ambulatory COVID-19 patients infected with the Beta, Delta or Omicron variants. S. Jaumdally, M. Tomasicchio, A. Pooran, A. Esmail, A. Kotze, S. Meier, L. Wilson, S. Oelofse, C. van der Merwe, A. Roomaney, M. Davids, T. Suliman, R. Joseph, T. Perumal, A. Scott, M. Shaw, W. Preiser, C. Williamson, A. Goga, E. Mayne, G. Gray, P. Moore, A. Sigal, J. Limberis, J. Metcalfe, K. Dheda. Nature Communications
- Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters. Yolandy Lemmer, Ros Chapman, Celia Abolnik, Tanja Smith, Georgia Schäfer, Tandile Hermanus, Ilse du Preez, Kruger Goosen, Kamogelo M. Sepotokele, Sophette Gers, Tasnim Suliman, Wolfgang Preiser, Megan L. Shaw, Robyn Roth, Alma Truyts, John Chipangura, Martin Magwaza, Osborn Mahanjana, Penny L. Moore, Martha M. O'Kennedy. Vaccine
- Proteomic and genetic analyses of influenza A viruses identify pan-viral host targets. Kelsey M. Haas, Michael J. McGregor, Mehdi Bouhaddou, Benjamin J. Polacco, Eun Young Kim, Thong T. Nguyen, Billy W. Newton, Matthew Urbanowski, Heejin Kim, Michael A.P. Williams, Veronica V. Rezelj, Alexandra Hardy, Andrea Fossati, Erica J. Stevenson, Ellie Sukerman, Tiffany Kim, Sudhir Penugonda, Elena Moreno, Hannes Braberg, Yuan Zhou, Giorgi Metreveli, Bhavya Harjai, Tia A. Tummino, James E. Melnyk, Margaret Soucheray, Jyoti Batra, Lars Pache, Laura Martin-Sancho, Jared Carlson-Stevermer, Alexander S. Jureka, Christopher F. Basler, Kevan M. Shokat, Brian K. Shoichet, Leah P. Shriver, Jeffrey R. Johnson, Megan L. Shaw, Sumit K. Chanda, Dan M. Roden, Tonia C. Carter, Leah C. Kottyan, Rex L. Chisholm, Jennifer A. Pacheco, Maureen E. Smith, Steven J. Schrodi, Randy A. Albrecht, Marco Vignuzzi, Lorena Zuliani-Alvarez, Danielle L. Swaney, Manon Eckhardt, Steven M. Wolinsky, Kris M. White, Judd F. Hultquist, Robyn M. Kaake, Adolfo García-Sastre, Nevan J. Krogan. Nature Communications
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Shaw has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Shaw has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.